Rigel Pharmaceuticals reported $94.4M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Celldex Therapeutics USD 60.52M 808K Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Veracyte USD 84.21M 21.47M Sep/2026